Cat. No.: HS-507 003
Amount: 50 µg
Price:
$370.00
|
|
|
| Cat. No. HS-507 003 |
50 µg specific antibody, lyophilized. Affinity purified with the immunogen. Albumin and azide were added for stabilization. For reconstitution add 50 µl H2O to get a 1mg/ml solution in PBS. Then aliquot and store at -20°C to -80°C until use. Antibodies should be stored at +4°C when still lyophilized. Do not freeze! |
| Applications | |
| Immunogen | Recombinant protein corresponding to residues near the central region of human MEF2A (UniProt Id: Q02078) |
| Remarks |
IHC: Heat-mediated antigen retrieval (citrate buffer pH 6) is required for immunohistochemical staining in mouse muscle section. |
| Data sheet | hs-507_003.pdf |
Important information|
|
MEF2A is a member of the MEF2 (myocyte enhancer factor 2) family of transcription factors. The MEF2 family includes three other members, MEF2B, -C and -D. MEF2A is ubiquitously expressed but has an alternatively spliced isoform that is restricted to skeletal muscle, heart and brain due to the inclusion of an exon encoding the peptide SEEEELEL (residues 289-296) (1). The activity of MEF2A can be regulated by phosphorylation/dephosphorylation, which affects its DNA-binding affinity and interaction with transcriptional co-activators and co-repressors. MEF2A is also susceptible to protease cleavage by caspases (2). In neuronal cells, MEF2A plays a role in neurodevelopment and synaptic plasticity. It contributes to the formation and maintenance of neural circuits, ultimately impacting cognitive functions and behavior. MEF2A also has an important role in the immune system. It contributes significantly to the development of T-cells and the immune response. MEF2A is a non-redundant regulator of the inflammatory epigenome of macrophages and, more specifically, of PGE2-sensitive enhancers (3). Defects in MEF2A may be a cause of an autosomal dominant form of coronary artery disease (CAD) with myocardial infarction (ADCAD1) [MIM:608320] (4). MEF2A protein is also regulated in a model of chronic kidney disease using cadmium as a toxic treatment in human proximal tubule cells (HK-2) (5).